Thomas Heigle, MD
Ophthalmology · Baton Rouge, LANPI 1174573711
Payments from drug & device makers
Across 154 payments — averaging $30.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- Glaukos Corporation$480
- AbbVie$417
- Biotissue Holdings Inc.$333
- Oyster Point Pharma, Inc.$195
- Dompe US, Inc.$180
- plus $724 from 14 others
What the payments were for
- Food & beverage$4,645100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 65 | $2,317 |
| Glaukos Corporation | 8 | $480 |
| AbbVie(2 entities) | 20 | $417 |
| Biotissue Holdings Inc. | 12 | $333 |
| Oyster Point Pharma, Inc. | 10 | $195 |
| Dompe US, Inc. | 7 | $180 |
| Tarsus Pharmaceuticals, Inc. | 10 | $178 |
| Rxsight Inc | 1 | $121 |
| Kala Pharmaceuticals, Inc. | 5 | $120 |
| Eyevance Pharmaceuticals LLC | 3 | $54 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $42 |
| Bausch & Lomb Americas Inc. | 2 | $38 |
| Sun Pharmaceutical Industries Inc. | 2 | $33 |
| Harrow Eye, LLC | 1 | $23 |
| Mallinckrodt Hospital Products Inc. | 1 | $23 |
| Ivantis, Inc | 1 | $22 |
| Shire North American Group Inc | 1 | $21 |
| Aerie Pharmaceuticals, Inc. | 1 | $19 |
| Thea Pharma Inc. | 1 | $15 |
| Novartis | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,645 in reported general payments places this provider in the 75th percentile of 286 ophthalmology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 24 | $798,335 |
| RestasisCyclosporine | 133 | $127,773 |
| Prednisolone Acetate | 622 | $32,988 |
| Loteprednol Etabonate | 147 | $26,856 |
| Fluorometholone | 235 | $22,440 |
| XiidraLifitegrast | 14 | $22,279 |
| Lotemax SmLoteprednol Etabonate | 77 | $19,550 |
| Cyclosporine | 35 | $15,124 |
| EysuvisLoteprednol Etabonate | 29 | $14,867 |
| MieboPerfluorohexyloctane/Pf | 17 | $12,583 |
| LumiganBimatoprost | 27 | $11,458 |
| CombiganBrimonidine Tartrate/Timolol | 30 | $8,216 |
| Brimonidine Tartrate | 147 | $7,726 |
| IlevroNepafenac | 21 | $7,636 |
| ValacyclovirValacyclovir Hcl | 143 | $5,913 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $180 | $798,33524 claims |
| AbbVieRestasis, Lumigan, Combigan | $417 | $147,447190 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Lotemax Sm, Prolensa | $42 | $51,538239 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $38 | $34,86231 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $120 | $14,86729 claims |
| NovartisIlevro | $14 | $7,63621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 286 ophthalmology providers in Louisiana.
Other ophthalmology in Baton Rouge
- Blake WilliamsonBaton Rouge$482K
- Thomas StuckeyBaton Rouge$28K
- Charles WilliamsonBaton Rouge$16K
- David FargasonBaton Rouge$6K
- Philip EhrlichBaton Rouge$6K
- Daniel NelsonBaton Rouge$6K
- Michael MorganBaton Rouge$6K
- George FivgasBaton Rouge$6K
- William ReadMonroe$303K
- Delmar CaldwellNew Orleans$282K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.